Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
90Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.23M | $-28.62M | $-1.34 |
| 2024 | $0.00 | $-25.13M | $-2.39 |
| 2023 | $0.00 | $-30.15M | $-3.98 |
| 2022 | $0.00 | $-39.75M | $-0.60 |
| 2021 | $0.00 | $-93.06M | $-7.44 |
Social Signal Score
Earnings
Mon, Nov 16(in 3 months)
Consensus estimate $-0.11 per share
Typical surprise -50.0% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-0.18 vs $-0.11miss
- Fri, May 15$-0.04 vs $-0.05beat
- Mon, Mar 23$0.19 vs $-0.09beat
- Fri, Nov 14$-0.18 vs $-0.11miss
- Mon, Aug 18$-0.98 vs $-0.15miss
- Thu, May 15$-0.34 vs $-0.30miss
Estimates and results for NRXP via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
NRXPhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (2)
- Newsseekingalpha.com·5d ago·Positive
NRx Pharmaceuticals, Inc. (NRXP) Discusses FDA First Cycle Review Outcome and Commercialization Plans for Preservative Free Ketamine Transcript NRx Pharmaceuticals, Inc. (NRXP) Discusses FDA First Cycle Review Outcome and Commercialization Plans for Preservative Free Ketamine Transcript
View source ↗ - Newsmarketbeat.com·5d ago·Negative
NRx Pharmaceuticals Nears FDA Decision on Preservative-Free Ketamine After Review Clears Hurdles NRx Pharmaceuticals NASDAQ: NRXP said it has completed the first-cycle U.S. Food and Drug Administration review of its abbreviated new drug application, or ANDA, for preservative-free ketamine, with one remaining issue related to the product's vial connector.
View source ↗